ViralClear Pharmaceuticals

ViralClear Pharmaceuticals is a company primarily focused on producing an oral broad-spectrum antiviral drug for the treatment of COVID-19. Merimepodib is designed for oral administration and has demonstrated broad-spectrum antiviral activity in vitro, including potent activity against COVID-19 in cell cultures. Merimepodib has previously been studied in 12 clinical trials, five of which were conducted in patients with hepatitis C (one Phase 1b, one Phase 2, two Phase 2a, and one Phase 2b), one in patients with psoriasis (Phase 2), and six in healthy volunteers (Phase 1).